BioSpace News Archive

Drug Development

SEC Wades into Confusion Over FibroGen Safety Data in Anemia Drug

FibroGen is tangled up in a Securities Class Action Litigation and Derivative Litigation concerning clinical trial data for its drug Roxadustat.

March 2, 2022
·
3 min read
·
Mark Terry
Policy

Biden Pledges to Provide Free COVID-19 Treatment Following Positive Tests

President Biden announced updates to the “Test to Treat” initiative that will allow people to get tested for COVID at a pharmacy and receive a treatment round of Pfizer’s Paxlovid at no cost.

March 2, 2022
·
3 min read
·
Alex Keown
NEW PRESS GANEY REPORT SHOWS 83% OF CONSUMERS ARE MORE LIKELY TO USE PHARMACEUTICAL CONSUMER BRAND WEBSITES WITH PROVIDER DIRECTORIES

Consumers look to pharma brands to provide reliable information, a streamlined path to care.

March 2, 2022
·
3 min read
Drug Development

Elgan’s Infant Malabsorption Treatment Reduces Complications in Phase III

The Phase III study showed that ELGN-GI not only improved gastrointestinal (GI) function, but it also reduced life-threatening complications.

March 2, 2022
·
3 min read
·
Claudia Beezhold
Policy

Lessons from Past Wars Could Offer Insight for Biopharma During Ukraine War

Throughout history, many different countries have had their biopharma supply chains changed – sometimes profitably, sometimes detrimentally – by war.

March 2, 2022
·
6 min read
·
Hannah Chudleigh
Business

Vesalius, Rondo Debut to Redefine Treatment Paradigms

Flagship will pour in $75 million into Vesalius to support its beginnings, while Rondo raised $67 million to support the development of its preclinical pipeline.

March 2, 2022
·
3 min read
·
Vanessa Doctor, RN
Business

Adagene and Sanofi Tie Up in $2.5B Antibody Collab

Shares of Adagene Inc. are up more than 10% in premarket trading after the company announced a monoclonal and bispecific antibody collaboration with Sanofi valued at up to $2.5 billion.

March 2, 2022
·
3 min read
·
Alex Keown
Drug Development

Karyopharm’s Endometrial Cancer Treatment Hits FDA Roadblock

After Karyopharm submitted Phase III data from its SIENDO study on Selinexor, the FDA said that it is unlikely to support an sNDA approval for the drug.

March 2, 2022
·
3 min read
·
Hannah Chudleigh
FDA

Pfizer’s RSV Vaccine Reaches “Pivotal Next Step” with Breakthrough Therapy Designation

Pfizer announced its RSV vaccine candidate PF-06482077 or RSVpreF, received Breakthrough Therapy designation from the U.S. Food and Drug Administration.

March 2, 2022
·
2 min read
·
Alex Keown
Business

Global Roundup: PneumoWave’s Opioid Overdose Device, Sputnik V and German Innovation

Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

March 2, 2022
·
3 min read
·
Alex Keown